Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,348 | 188 | 1,113 |
| Samples | 287 | 65 | 212 |
| Peptides | 245 | 43 | 197 |
Function
FERMT2 · FERM domain containing kindlin 2
Enables several functions, including actin binding activity; phosphatidylinositol-3,4,5-trisphosphate binding activity; and type I transforming growth factor beta receptor binding activity. Involved in several processes, including cell surface receptor signaling pathway; positive regulation of cell differentiation; and positive regulation of cellular component biogenesis. Acts upstream of or within cell adhesion and protein localization to cell junction. Located in cytosol; focal adhesion; and nucleoplasm. Is extrinsic component of cytoplasmic side of plasma membrane. Part of adherens junction and plasma membrane. Biomarker of acute myeloid leukemia. [provided by Alliance of Genome Resources, Apr 2022]
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 230 amino-acid changes on canonical ENST00000341590 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in FERMT2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FERMT2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Endometrial Carcinoma | 5/42 12% | 18/612 3% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Hodgkins Lymphoma | 0/16 0% | 3/122 2% |
| Germ Cell Tumour | 3/25 12% | 0/169 0% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 1/71 1% |
| Colorectal Carcinoma | 8/143 6% | 39/3239 1% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 11/1390 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Melanoma | 2/210 1% | 21/1899 1% |
| Other Solid Cancers | 3/94 3% | 12/1515 1% |
| Cervical Carcinoma | 2/35 6% | 2/422 0% |
| Gastric Carcinoma | 0/74 0% | 16/1809 1% |
| Esophageal Squamous Cell Carcinoma | 5/51 10% | 14/2550 1% |
| Bladder Carcinoma | 2/58 3% | 5/956 1% |
| Esophageal Carcinoma | 1/23 4% | 4/769 1% |
| Hepatocellular Carcinoma | 0/46 0% | 14/2210 1% |
| Plasma Cell Myeloma | 0/44 0% | 2/305 1% |
| Ovarian Carcinoma | 3/109 3% | 3/998 0% |
| Non-Cancerous | 1/104 1% | 4/830 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 4/810 0% |
| Breast Carcinoma | 5/144 3% | 10/3264 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Head and Neck Carcinoma | 1/85 1% | 6/1574 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| B-Cell Non-Hodgkins Lymphoma | 4/88 5% | 6/2534 0% |
| Kidney Carcinoma | 0/85 0% | 7/1862 0% |
| Glioma | 0/52 0% | 7/2127 0% |
Mutation Distribution
Where FERMT2 is mutated · all tissues, split by cell line vs tissue
How many mutations in FERMT2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,348 mutations in FERMT2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|